Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: A placebo-controlled study

Página do item simplificado
dc.contributor.authorNascimento M.M.
dc.contributor.authorSuliman M.E.
dc.contributor.authorSilva M.
dc.contributor.authorChinaglia T.
dc.contributor.authorMarchioro J.
dc.contributor.authorHayashi S.Y.
dc.contributor.authorRiella M.C.
dc.contributor.authorLindholm B.
dc.contributor.authorAnderstam B.
dc.date.accessioned2024-03-13T01:31:40Z
dc.date.available2024-03-13T01:31:40Z
dc.date.issued2010
dc.description.abstractBackground: Inflammation and oxidative stress (OS) are cardiovascular risk factors in patients with chronic kidney disease. N-acetylcysteine (NAC) is a thiol-containing antioxidant with anti-inflammatory properties and has been shown to reduce the number of cardiovascular events in hemodialysis patients. Methods: The current study aimed to determine the effect of oral NAC (2 × 600 mg/daily) on plasma levels of inflammatory and OS markers in peritoneal dialysis (PD) patients. We performed a placebo-controlled study over 8 weeks in 30 patients (40% males, age 52 ± 13 years) on regular PD. Before the study was started, the patients were divided into 2 groups of 15 patients matched for age and gender. 22 patients completed the study (12 on NAC, 10 on placebo). Proinflammatory cytokines [high-sensitivity C-reactive protein, interleukin-6 (IL-6), tumor necrosis factor-alpha, and pentraxin 3] and markers of OS (pentosidine, advanced oxidation protein products, homocysteine, glutathione, asymmetric dimethylarginine, and free sulfhydryls) were measured before and after treatment with NAC. Results: Treatment with NAC for 8 weeks increased mean baseline plasma NAC levels from 2.6 to 24.8 μμmol/L (p = 0.007). This intervention, which caused no side effects, significantly diminished IL-6 levels, from 9.4 (4.5 - 31) to 7.6 (4.9 - 13.5) pg/mL (p = 0.006), whereas no such changes were observed in the placebo group. NAC treatment did not significantly affect the other inflammatory and OS markers. Conclusion: Short-term oral NAC treatment resulted in reduction of circulating IL-6, suggesting that such treatment could be a useful strategy in blunting the inflammatory response in PD patients. © 2010 International Society for Peritoneal Dialysis.
dc.description.firstpage336
dc.description.issuenumber3
dc.description.lastpage342
dc.description.volume30
dc.identifier.doi10.3747/pdi.2009.00073
dc.identifier.issn0896-8608
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/37192
dc.relation.ispartofPeritoneal Dialysis International
dc.rightsAcesso Restrito
dc.subject.otherlanguageChronic kidney disease
dc.subject.otherlanguageInflammation
dc.subject.otherlanguageN-acetylcysteine
dc.subject.otherlanguageOxidative stress
dc.titleEffect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: A placebo-controlled study
dc.typeArtigo
local.scopus.citations94
local.scopus.eid2-s2.0-77957678999
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77957678999&origin=inward
Arquivos
Coleções
Artigos de periódico